NO20040534L - Spiroforbindelser - Google Patents

Spiroforbindelser

Info

Publication number: NO20040534L
Authority: NO; Norway
Prior art keywords: alk; optionally substituted; aryl; nhalk; oalk
Prior art date: 2001-08-07

Application number

NO20040534A

Other languages

English (en)

Norwegian (no)

Inventor

Takehiro Fukami

Katsumasa Nonoshita

Takeshi Sagara

Hiroyuki Kishino

Original Assignee

Banyu Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-07

Filing date

2004-02-05

Publication date

2004-03-23

2004-02-05 Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd

2004-03-23 Publication of NO20040534L publication Critical patent/NO20040534L/no

Links

150000003413 spiro compounds Chemical class 0.000 title abstract 3
125000003118 aryl group Chemical group 0.000 abstract 5
125000001475 halogen functional group Chemical group 0.000 abstract 3
125000002947 alkylene group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
125000000753 cycloalkyl group Chemical group 0.000 abstract 2
125000004438 haloalkoxy group Chemical group 0.000 abstract 2
125000001188 haloalkyl group Chemical group 0.000 abstract 2
125000001072 heteroaryl group Chemical group 0.000 abstract 2
125000002768 hydroxyalkyl group Chemical group 0.000 abstract 2
101500025005 Homo sapiens Neuropeptide Y Proteins 0.000 abstract 1
208000001953 Hypotension Diseases 0.000 abstract 1
125000003342 alkenyl group Chemical group 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
230000001195 anabolic effect Effects 0.000 abstract 1
230000000202 analgesic effect Effects 0.000 abstract 1
230000001539 anorectic effect Effects 0.000 abstract 1
230000002075 anti-alcohol Effects 0.000 abstract 1
230000001773 anti-convulsant effect Effects 0.000 abstract 1
230000001430 anti-depressive effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000003110 anti-inflammatory effect Effects 0.000 abstract 1
230000002402 anti-lipaemic effect Effects 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
239000000935 antidepressant agent Substances 0.000 abstract 1
229940005513 antidepressants Drugs 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1
239000002249 anxiolytic agent Substances 0.000 abstract 1
230000000949 anxiolytic effect Effects 0.000 abstract 1
125000000732 arylene group Chemical group 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
206010061428 decreased appetite Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
XKWCTHKJQNUFOQ-HRPSIEBRSA-N gtpl1504 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 XKWCTHKJQNUFOQ-HRPSIEBRSA-N 0.000 abstract 1
125000005549 heteroarylene group Chemical group 0.000 abstract 1
125000001183 hydrocarbyl group Chemical group 0.000 abstract 1
208000021822 hypotensive Diseases 0.000 abstract 1
230000001077 hypotensive effect Effects 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
230000001777 nootropic effect Effects 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229940125725 tranquilizer Drugs 0.000 abstract 1
239000003204 tranquilizing agent Substances 0.000 abstract 1
230000002936 tranquilizing effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Addiction (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20040534A 2001-08-07 2004-02-05 Spiroforbindelser NO20040534L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001239567		2001-08-07
PCT/JP2002/007922 WO2003014083A1 (en)	2001-08-07	2002-08-02	Spiro compounds

Publications (1)

Publication Number	Publication Date
NO20040534L true NO20040534L (no)	2004-03-23

Family

ID=19070298

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20040534A NO20040534L (no)	2001-08-07	2004-02-05	Spiroforbindelser

Country Status (18)

Country	Link
US (1)	US7205417B2 (ja)
EP (1)	EP1415986B1 (ja)
JP (1)	JP4341404B2 (ja)
KR (1)	KR20040023731A (ja)
CN (1)	CN1538956A (ja)
AT (1)	ATE427935T1 (ja)
AU (1)	AU2002323787B2 (ja)
BR (1)	BR0211740A (ja)
CA (1)	CA2456599A1 (ja)
DE (1)	DE60231880D1 (ja)
EA (1)	EA006964B1 (ja)
HU (1)	HUP0401108A2 (ja)
IL (1)	IL160139A0 (ja)
MX (1)	MXPA04001144A (ja)
NO (1)	NO20040534L (ja)
PL (1)	PL367983A1 (ja)
WO (1)	WO2003014083A1 (ja)
ZA (1)	ZA200400091B (ja)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6374762B1 (en) *	1997-10-27	2002-04-23	Correct Craft, Inc.	Water sport towing apparatus
ES2193875B2 (es) *	2002-04-09	2005-03-01	Laboratorios Del Dr. Esteve, S.A.	Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
US20040242572A1 (en) *	2002-08-24	2004-12-02	Boehringer Ingelheim International Gmbh	New carboxamide compounds having melanin concentrating hormone antagonistic activity, pharmaceutical preparations comprising these compounds and process for their manufacture
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
WO2004096139A2 (en)	2003-04-24	2004-11-11	Incyte Corporation	Aza spiro alkane derivatives as inhibitors of metalloproteases
WO2005097127A2 (en)	2004-04-02	2005-10-20	Merck & Co., Inc.	Method of treating men with metabolic and anthropometric disorders
KR20070050076A (ko) *	2004-08-10	2007-05-14	인사이트 산 디에고 인코포레이티드	아미도 화합물 및 약제로서의 이의 용도
US7879834B2 (en)	2004-08-19	2011-02-01	Vertex Pharmaceuticals Incorporated	Spiroindoline modulators of muscarinic receptors
US7786141B2 (en) *	2004-08-19	2010-08-31	Vertex Pharmaceuticals Incorporated	Dihydrospiroindene modulators of muscarinic receptors
JPWO2006028239A1 (ja) *	2004-09-07	2008-05-08	萬有製薬株式会社	カルバモイル置換スピロ誘導体
US7863449B2 (en) *	2004-11-29	2011-01-04	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
JP4371164B2 (ja) *	2005-11-10	2009-11-25	萬有製薬株式会社	アザ置換スピロ誘導体
CN101305009B (zh) *	2005-11-10	2012-01-11	Msdk.K.公司	氮杂取代的螺环衍生物
AU2006330866A1 (en) *	2005-12-22	2007-07-05	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
JP2009527568A (ja)	2006-02-22	2009-07-30	バーテックスファーマシューティカルズインコーポレイテッド	ムスカリン受容体の調節剤
JP2009527569A (ja) *	2006-02-22	2009-07-30	バーテックスファーマシューティカルズインコーポレイテッド	ムスカリン受容体の調節剤
US7910108B2 (en)	2006-06-05	2011-03-22	Incyte Corporation	Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
CN101500565A (zh) *	2006-06-29	2009-08-05	弗特克斯药品有限公司	毒蕈碱性受体的调节剂
US7696201B2 (en)	2006-08-15	2010-04-13	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
AU2007284350A1 (en) *	2006-08-18	2008-02-21	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
WO2008039327A2 (en)	2006-09-22	2008-04-03	Merck & Co., Inc.	Method of treatment using fatty acid synthesis inhibitors
CA2682727C (en)	2007-04-02	2016-03-22	Banyu Pharmaceutical Co., Ltd.	Indoledione derivative
AU2008261102B2 (en)	2007-06-04	2013-11-28	Bausch Health Ireland Limited	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009045519A1 (en) *	2007-10-03	2009-04-09	Vertex Pharmaceuticals Incorporated	Modulators of muscarinic receptors
EP2265588B1 (en) *	2008-02-27	2013-06-26	Vitae Pharmaceuticals, Inc.	INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1
EP3239170B1 (en)	2008-06-04	2019-03-20	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en)	2008-07-16	2010-01-21	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
AU2009307884B2 (en)	2008-10-22	2014-07-31	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102272103B (zh)	2008-10-30	2015-10-21	默沙东公司	异烟酰胺食欲素受体拮抗剂
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CN102656147A (zh) *	2009-12-11	2012-09-05	霍夫曼-拉罗奇有限公司	可用作ampk调节剂的螺吲哚-环丙烷二氢吲哚酮
WO2011069298A1 (en)	2009-12-11	2011-06-16	F. Hoffmann-La Roche Ag	Novel cyclopropane indolinone derivatives
US8895596B2 (en)	2010-02-25	2014-11-25	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
BR112013021236B1 (pt)	2011-02-25	2021-05-25	Merck Sharp & Dohme Corp	composto derivado de benzimidazol, e, composição
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
CN104583194A (zh)	2012-05-11	2015-04-29	艾伯维公司	作为nampt抑制剂的哒嗪和吡啶衍生物
PH12019502809B1 (en)	2012-06-13	2024-04-24	Incyte Holdings Corp	Substituted tricyclic compounds as fgfr inhibitors
AU2013296470B2 (en)	2012-08-02	2016-03-17	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9840512B2 (en)	2013-02-22	2017-12-12	Merck Sharp & Dohme Corp.	Antidiabetic bicyclic compounds
US9650375B2 (en)	2013-03-14	2017-05-16	Merck Sharp & Dohme Corp.	Indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
SMT201800127T1 (it)	2013-04-19	2018-05-02	Incyte Holdings Corp	Eterocilci biciclici come inibitori di fgfr
HRP20240805T1 (hr)	2013-06-05	2024-09-27	Bausch Health Ireland Limited	Ultra-pročišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i uporabe
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en)	2015-02-20	2017-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
SG10201913036RA (en)	2015-02-20	2020-02-27	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
EP3558298A4 (en)	2016-12-20	2020-08-05	Merck Sharp & Dohme Corp.	ANTIDIABETIC SPIROCHROMAN COMPOUNDS
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
JP2021523121A (ja)	2018-05-04	2021-09-02	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｆｇｆｒ阻害剤の固体形態及びその調製プロセス
WO2020167701A1 (en)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Pyrrolidine orexin receptor agonists
EP3924058B1 (en)	2019-02-13	2026-01-07	Merck Sharp & Dohme LLC	5-alkyl pyrrolidine orexin receptor agonists
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021026047A1 (en)	2019-08-08	2021-02-11	Merck Sharp & Dohme Corp.	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JOP20220083A1 (ar)	2019-10-14	2023-01-30	Incyte Corp	حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
IL293001A (en)	2019-12-04	2022-07-01	Incyte Corp	Derivatives of fgfr repressors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP7443625B2 (ja)	2020-08-18	2024-03-05	メルク・シャープ・アンド・ドーム・エルエルシー	ビシクロヘプタンピロリジンオレキシン受容体アゴニスト
CN112939864B (zh) *	2021-01-29	2022-05-06	中国医科大学	螺[苯并[c]氮杂-1,1’-环己基]-3-酮类化合物
US12065494B2 (en)	2021-04-12	2024-08-20	Incyte Corporation	Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
CA3220274A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
JP2024522188A (ja)	2021-06-09	2024-06-11	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式ヘテロ環

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5869489A (en) *	1996-03-25	1999-02-09	Merck & Co., Inc.	Trypthophan ureas as neurokinnin antagonists
GB2311523A (en) *	1996-03-25	1997-10-01	Merck & Co Inc	Tryptophan urea tachykinin receptor antagonists
AU1285499A (en)	1997-10-30	1999-05-24	Merck & Co., Inc.	Somatostatin agonists
DE69929235T2 (de)	1998-11-10	2006-08-24	Merck & Co., Inc.	Spiro-indole als y5-rezeptor antagonisten
AU6909300A (en)	1999-08-20	2001-03-19	Merck & Co., Inc.	Substituted ureas as cell adhesion inhibitors
US6803372B2 (en) *	1999-08-20	2004-10-12	Banyu Pharmaceutical Co., Ltd.	Spiro compounds
TWI279402B (en)	1999-08-20	2007-04-21	Banyu Pharma Co Ltd	Spiro compounds having NPY antagonistic activities and agents containing the same
WO2002022563A1 (en) *	2000-09-14	2002-03-21	Toray Industries, Inc.	Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient
BR0116113A (pt)	2000-12-12	2004-08-03	Neurogen Corp	Espiro[isobenzofuran-1,4'-piperidin]-3-onas e 3h-espiroisoben-zofuran-1,4'-piperidinas
US6939966B2 (en) *	2001-07-24	2005-09-06	Merck & Co., Inc.	Radiolabeled neuropeptide Y Y5 receptor antagonists

2002
- 2002-08-02 PL PL02367983A patent/PL367983A1/xx not_active Application Discontinuation
- 2002-08-02 IL IL16013902A patent/IL160139A0/xx unknown
- 2002-08-02 MX MXPA04001144A patent/MXPA04001144A/es unknown
- 2002-08-02 EA EA200400288A patent/EA006964B1/ru not_active IP Right Cessation
- 2002-08-02 US US10/485,955 patent/US7205417B2/en not_active Expired - Fee Related
- 2002-08-02 BR BR0211740-1A patent/BR0211740A/pt not_active IP Right Cessation
- 2002-08-02 AU AU2002323787A patent/AU2002323787B2/en not_active Ceased
- 2002-08-02 HU HU0401108A patent/HUP0401108A2/hu unknown
- 2002-08-02 DE DE60231880T patent/DE60231880D1/de not_active Expired - Lifetime
- 2002-08-02 AT AT02755790T patent/ATE427935T1/de not_active IP Right Cessation
- 2002-08-02 CA CA002456599A patent/CA2456599A1/en not_active Abandoned
- 2002-08-02 JP JP2003519033A patent/JP4341404B2/ja not_active Expired - Fee Related
- 2002-08-02 CN CNA028153073A patent/CN1538956A/zh active Pending
- 2002-08-02 KR KR10-2004-7001947A patent/KR20040023731A/ko not_active Withdrawn
- 2002-08-02 EP EP02755790A patent/EP1415986B1/en not_active Expired - Lifetime
- 2002-08-02 WO PCT/JP2002/007922 patent/WO2003014083A1/ja not_active Ceased
2004
- 2004-01-07 ZA ZA200400091A patent/ZA200400091B/en unknown
- 2004-02-05 NO NO20040534A patent/NO20040534L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2003014083A1 (en)	2003-02-20
KR20040023731A (ko)	2004-03-18
EP1415986A4 (en)	2005-11-02
EP1415986A1 (en)	2004-05-06
EA200400288A1 (ru)	2004-12-30
EP1415986B1 (en)	2009-04-08
EA006964B1 (ru)	2006-06-30
PL367983A1 (en)	2005-03-21
DE60231880D1 (de)	2009-05-20
BR0211740A (pt)	2004-09-28
JPWO2003014083A1 (ja)	2004-11-25
ATE427935T1 (de)	2009-04-15
US7205417B2 (en)	2007-04-17
US20040259890A1 (en)	2004-12-23
ZA200400091B (en)	2005-06-07
HUP0401108A2 (hu)	2004-09-28
AU2002323787B2 (en)	2008-04-24
CA2456599A1 (en)	2003-02-20
CN1538956A (zh)	2004-10-20
JP4341404B2 (ja)	2009-10-07
IL160139A0 (en)	2004-06-20
MXPA04001144A (es)	2004-07-08

Publication	Publication Date	Title
NO20040534L (no)	2004-03-23	Spiroforbindelser
DE60330407D1 (de)	2010-01-14	Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
DE602004005886D1 (de)	2007-05-24	Derivate von n-äphenyl(alkylpiperidin-2-yl)methylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
PT1349843E (pt)	2005-09-30	Derivados de tiazolo e de oxazolo como activadores dos receptores activados por proliferadores de peroxissomas humanos
RU2004134564A (ru)	2005-08-10	Химические соединения
TW345575B (en)	1998-11-21	Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound
ATE496622T1 (de)	2011-02-15	Verwendung von thienopyridonderivaten als ampk- aktivatoren und pharmazeutische zusammensetzungen,die diese enthalten
IL145830A0 (en)	2002-07-25	Pharmaceutical compositions containing a compound which activates a receptor for glucagon-like peptide-1
DE69208088D1 (de)	1996-03-14	Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
ATE206122T1 (de)	2001-10-15	Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
AR035320A1 (es)	2004-05-12	Compuestos activadores de hppardelta, composicion farmaceutica, su uso en la preparacion de medicamentos, metodo para el tratamiento de enfermedades mediadas por hppardelta
DE602004006891D1 (de)	2007-07-19	Derivate von n-äphenyl(pyrrolidin-2-yl)methylübenzamid und n-ä(azepan-2-yl)phenylmethylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika
RU2009147775A (ru)	2011-08-27	Замещенные производные гетероарилпиперидина в качестве модуляторов рецептора меланокортина-4
ATE125252T1 (de)	1995-08-15	Cyano-2-hydroxy-3-enamid-derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, diese enthaltende pharmazeutische zusammensetzungen und erhaltene zwischenprodukte.
CY1110613T1 (el)	2015-04-29	Υποκατεστημενες θειαζολες και η χρησιμοποιηση τους για την παρασκευη φαρμακων
BR9707566A (pt)	1999-07-27	Derivados feniletanolamino tetralincarboxamida 3,4-dissubstituidos
ATE250586T1 (de)	2003-10-15	Imidazoline derivate,ihre herstellung und pharmazeutische zusammensetzungen die sie enthalten
ATE234098T1 (de)	2003-03-15	4-aminopyrrole (3,2-d) pyrimidinen als antagonisten des neuropeptide y receptors
ATE124685T1 (de)	1995-07-15	4-phenylmethyl-1h-indol-derivate, verfahren und zwischenverbindungen zu deren herstellung, anwendung als arzneimittel und diese enthaltende zusammensetzungen.
DE502006007450D1 (de)	2010-08-26	Neue, zyklisch substituierte furopyrimidin-derivate und ihre verwendung zur behandlung von kardiovaskulären erkrankungen
DE602005024788D1 (de)	2010-12-30	14,15-dihydro-20,21-dinoreburnamenin-14-ol-derivate und deren anwendung
ES2189355T3 (es)	2003-07-01	Compuestos de benzotiofeno como agentes antitromboticos e intermedios.
ATE83484T1 (de)	1993-01-15	20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.
UY24465A1 (es)	2000-09-29	Antagonistas oxadiazol y tiadiazol del receptor muscarinico

Legal Events

Date	Code	Title	Description
2007-03-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application